Stocks of Syros Pharmaceuticals Inc. (SYRS) are poised to climb above their peers

Syros Pharmaceuticals Inc. (NASDAQ: SYRS) stock fell -4.90% on Friday to $0.93 against a previous-day closing price of $0.98. With 1.05 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.86 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.0500 whereas the lowest price it dropped to was $0.8501. The 52-week range on SYRS shows that it touched its highest point at $5.64 and its lowest point at $0.65 during that stretch. It currently has a 1-year price target of $9.60. Beta for the stock currently stands at 1.65.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SYRS was up-trending over the past week, with a rise of 13.51%, but this was up by 7.45% over a month. Three-month performance surged to 5.57% while six-month performance fell -46.71%. The stock lost -81.11% in the past year, while it has lost -71.56% so far this year. A look at the trailing 12-month EPS for SYRS yields -1.55 with Next year EPS estimates of -1.03. For the next quarter, that number is -0.41. This implies an EPS growth rate of 24.20% for this year and 8.00% for next year.

Float and Shares Shorts:

At present, 63.06 million SYRS shares are outstanding with a float of 59.69 million shares on hand for trading. On Jul 14, 2022, short shares totaled 2.05 million, which was 3.25% higher than short shares on Jun 14, 2022. In addition to Dr. Nancy A. Simonian M.D. as the firm’s Pres, CEO & Director, Dr. Richard A. Young Ph.D. serves as its Scientific Founder, Member of Scientific Advisory Board & Director.

Institutional Ownership:

Through their ownership of 70.64% of SYRS’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 29.99% of SYRS, in contrast to 29.88% held by mutual funds. Shares owned by individuals account for 13.44%. As the largest shareholder in SYRS with 8.80% of the stake, Fidelity Management & Research Co holds 5,526,376 shares worth 5,526,376. A second-largest stockholder of SYRS, BlackRock Fund Advisors, holds 3,837,492 shares, controlling over 6.11% of the firm’s shares. Invus Public Equities Advisors LL is the third largest shareholder in SYRS, holding 3,500,000 shares or 5.57% stake. With a 2.58% stake in SYRS, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,617,578 shares are owned by the mutual fund manager. The Fidelity Select Port. – Biotechno, which owns about 1.66% of SYRS stock, is the second-largest Mutual Fund holder. It holds 1,045,057 shares valued at 1.01 million. Vanguard Extended Market Index Fu holds 1.24% of the stake in SYRS, owning 779,586 shares worth 0.75 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2022, SYRS reported revenue of $5.47M and operating income of -$26.65M. Over the past year, revenue came in at $24.13M while operating income stood at -$105.13M. It generated -$25.15M net income for the quarter, which came to -$97.48M over the last twelve months. The EBITDA in the recently reported quarter was -$25.87M and diluted EPS was -$0.40. EBITDA for the full year was -$101.99M.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SYRS since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SYRS analysts setting a high price target of $19.00 and a low target of $4.00, the average target price over the next 12 months is $9.50. Based on these targets, SYRS could surge 1943.01% to reach the target high and rise by 330.11% to reach the target low. Reaching the average price target will result in a growth of 921.51% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. SYRS will report FY 2022 earnings on 03/14/2023. Analysts have provided yearly estimates in a range of -$0.70 being high and -$1.95 being low. For SYRS, this leads to a yearly average estimate of -$1.17. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Syros Pharmaceuticals Inc. surprised analysts by $0.07 when it reported -$0.40 EPS against a consensus estimate of -$0.47. The surprise factor in the prior quarter was $0.08. Based on analyst estimates, the high estimate for the next quarter is -$0.16 and the low estimate is -$0.51. The average estimate for the next quarter is thus -$0.38.

Summary of Insider Activity:

Insiders traded SYRS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 5 over the past year. The total number of shares bought during that period was 0 while 129,753 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *